NCT02159469View on ClinicalTrials.gov

Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

November 30, 2015

Conditions
Hypogonadism
Interventions
COMBINATION_PRODUCT

Testosterone enanthate auto-injector

Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels

Trial Locations (28)

Unknown

Birmingham

Huntsville

Tucson

Burbank

Torrance

Upland

Jacksonville

Oviedo

Lexington

Shreveport

Brookline

Methuen

Kansas City

Lawrenceville

Albany

New York

Rochester

Franklin

Medford

Warwick

Mt. Pleasant

Nashville

San Antonio

Sugar Land

West Valley City

Norfolk

Richmond

Renton

Sponsors
All Listed Sponsors
lead

Antares Pharma Inc.

INDUSTRY

NCT02159469 - Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism | Biotech Hunter | Biotech Hunter